

Genital Herpes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/G5395999BF9EEN.html>

Date: April 2022

Pages: 86

Price: US\$ 2,000.00 (Single User License)

ID: G5395999BF9EEN

Abstracts

Genital Herpes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Genital Herpes - Drugs In Development, 2022, provides an overview of the Genital Herpes (Infectious Disease) pipeline landscape.

Genital herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused by the herpes simplex virus (HSV). Symptoms include decreased appetite, fever, general sick feeling (malaise), muscle aches in the lower back, buttocks, thighs, or knees and swollen and tender lymph nodes in the groin during an outbreak. Treatment includes antiviral medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Genital Herpes - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Genital Herpes (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Genital Herpes (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 2, 21 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Genital Herpes (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Genital Herpes (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Genital Herpes (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Genital Herpes (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Genital Herpes (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Genital Herpes (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Genital Herpes (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Genital Herpes (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Genital Herpes - Overview

Genital Herpes - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Genital Herpes - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Genital Herpes - Companies Involved in Therapeutics Development

Genital Herpes - Drug Profiles

Genital Herpes - Dormant Projects

Genital Herpes - Discontinued Products

Genital Herpes - Product Development Milestones

Featured News & Press Releases

Oct 18, 2021: United BioPharma, Shanghai Public Health Clinical Centre and Cheng Kung University partner on world's first long-acting Herpes Treatment UB-621

Jul 22, 2021: Rational Vaccines receives UK MHRA Innovation Passport for RVx201 for the treatment of genital herpes resulting from herpes simplex type 2 (HSV-2) virus

Nov 10, 2020: United BioPharma received IND approval from China NMPA for UB-621 Phase 2 trial in patients with Recurrent Genital Herpes

Sep 20, 2019: New Penn-Developed Vaccine Prevents Herpes in Mice, Guinea Pigs

Jun 10, 2019: United BioPharma receives US FDA approval for UB-621 Phase 2 trial in recurrent Genital Herpes Patients

Dec 06, 2017: Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates

May 04, 2017: Admedus Releases Results of HSV-2 Phase IIa Study

Mar 06, 2017: NanoBio Receives SBIR Grant For Genital Herpes Vaccine

Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes

Oct 19, 2016: Admedus Announces Positive Unblinded HSV-2 Phase II Interim Data

Mar 04, 2016: Interim HSV-2 Phase II clinical trial data encouraging

Feb 03, 2016: Model helps decide drug dose for clinical testing

Nov 15, 2015: IND submission of a phase I clinical trial for UB-621, an Anti-HSV-gD antibody, was approved by Taiwan Food and Drug Administration (TFDA)

Sep 22, 2015: NanoBio's Genital Herpes Vaccine Demonstrates Efficacy In Guinea Pigs As Both A Prophylactic And A Therapeutic Vaccine

Aug 17, 2015: Vaxart to Present at the 6th Euro Global Summit and Expo on Vaccines and Vaccination in Birmingham, UK on August 18, 2015

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Genital Herpes, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Genital Herpes - Pipeline by Abivax SA, 2022
Genital Herpes - Pipeline by AiCuris Anti-infective Cures AG, 2022
Genital Herpes - Pipeline by AlphaVax Inc, 2022
Genital Herpes - Pipeline by Anteris Technologies Ltd, 2022
Genital Herpes - Pipeline by Astellas Pharma Inc, 2022
Genital Herpes - Pipeline by Auritec Pharmaceuticals Inc, 2022
Genital Herpes - Pipeline by Auro Vaccines LLC, 2022
Genital Herpes - Pipeline by Biomere LLC, 2022
Genital Herpes - Pipeline by BioNTech SE, 2022
Genital Herpes - Pipeline by BlueWillow Biologics Inc, 2022
Genital Herpes - Pipeline by Brandenburg Antiinfektiva GmbH, 2022
Genital Herpes - Pipeline by GlaxoSmithKline Plc, 2022
Genital Herpes - Pipeline by iosBio Pharma Ltd, 2022
Genital Herpes - Pipeline by NanoViricides Inc, 2022
Genital Herpes - Pipeline by Nykode Therapeutics AS, 2022
Genital Herpes - Pipeline by Rational Vaccines Inc, 2022
Genital Herpes - Pipeline by Sanofi, 2022
Genital Herpes - Pipeline by Shulov Innovative Science Ltd, 2022
Genital Herpes - Pipeline by SL VaxiGen Inc, 2022
Genital Herpes - Pipeline by Starpharma Holdings Ltd, 2022
Genital Herpes - Pipeline by United BioPharma Inc, 2022
Genital Herpes - Pipeline by Vaxart Inc, 2022
Genital Herpes - Pipeline by Vir Biotechnology Inc, 2022
Genital Herpes - Pipeline by Vironova Medical AB, 2022
Genital Herpes - Pipeline by Wuhan Binhui Biotechnology Co Ltd, 2022

Genital Herpes - Dormant Projects, 2022
Genital Herpes - Dormant Projects, 2022 (Contd..1)
Genital Herpes - Dormant Projects, 2022 (Contd..2)
Genital Herpes - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Genital Herpes, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Genital Herpes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/G5395999BF9EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5395999BF9EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

